HK1259386A1 - 与白介素-33 (il-33)介导的疾病有关的生物标志物及其用途 - Google Patents
与白介素-33 (il-33)介导的疾病有关的生物标志物及其用途Info
- Publication number
- HK1259386A1 HK1259386A1 HK19101754.3A HK19101754A HK1259386A1 HK 1259386 A1 HK1259386 A1 HK 1259386A1 HK 19101754 A HK19101754 A HK 19101754A HK 1259386 A1 HK1259386 A1 HK 1259386A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- methods
- interleukin
- antagonist
- biomarkers
- disorder
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57527—Calcitonin gene related peptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/585—Calcitonins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562237624P | 2015-10-06 | 2015-10-06 | |
| US62/237,624 | 2015-10-06 | ||
| PCT/US2016/055502 WO2017062456A2 (en) | 2015-10-06 | 2016-10-05 | Biomarkers related to interleukin-33 (il-33)-mediated diseases and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1259386A1 true HK1259386A1 (zh) | 2019-11-29 |
Family
ID=57223756
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK19101754.3A HK1259386A1 (zh) | 2015-10-06 | 2016-10-05 | 与白介素-33 (il-33)介导的疾病有关的生物标志物及其用途 |
| HK18115046.2A HK1255972A1 (zh) | 2015-10-06 | 2016-10-05 | 与白介素-33(il-33)介导的疾病有关的生物标志物及其用途 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK18115046.2A HK1255972A1 (zh) | 2015-10-06 | 2016-10-05 | 与白介素-33(il-33)介导的疾病有关的生物标志物及其用途 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10005834B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3359567A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6858182B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102687412B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN108137682A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016333903B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3000725A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA201890891A1 (cg-RX-API-DMAC7.html) |
| HK (2) | HK1259386A1 (cg-RX-API-DMAC7.html) |
| MA (1) | MA50638A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2018004170A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017062456A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102400060B1 (ko) | 2013-12-26 | 2022-05-19 | 미쓰비시 타나베 파마 코퍼레이션 | 인간 항 il-33 중화 단일클론 항체 |
| SG10201805934RA (en) | 2014-01-10 | 2018-08-30 | Anaptysbio Inc | Antibodies directed against interleukin-33 (il-33) |
| US20160168640A1 (en) | 2014-11-10 | 2016-06-16 | Genentech, Inc. | Therapeutic and diagnostic methods for il-33-mediated disorders |
| KR20170080604A (ko) | 2014-11-10 | 2017-07-10 | 제넨테크, 인크. | 항-인터류킨-33 항체 및 그것의 용도 |
| KR102687412B1 (ko) | 2015-10-06 | 2024-07-24 | 리제너론 파아마슈티컬스, 인크. | 인터루킨-33(il-33)-매개된 질환과 관련된 바이오마커 및 이의 용도 |
| EA037960B1 (ru) | 2016-04-27 | 2021-06-15 | Эббви Инк. | Способ лечения эозинофильного эзофагита с применением антитела против il-13 |
| SG11201808693WA (en) | 2016-04-27 | 2018-11-29 | Pfizer | Anti-il-33 antibodies, compositions, methods and uses thereof |
| CN110431240A (zh) | 2017-04-13 | 2019-11-08 | 雷杰纳荣制药公司 | 在编码il33和il1rl1的基因中具有风险等位基因的患者的炎症性肺部疾病的治疗和抑制 |
| JP7657440B2 (ja) | 2017-06-12 | 2025-04-07 | ブルーフィン バイオメディシン， インコーポレイテッド | 抗－ｉｌ１ｒａｐ抗体および抗体薬物コンジュゲート |
| CN115920041A (zh) * | 2017-08-31 | 2023-04-07 | 田边三菱制药株式会社 | 含有il-33拮抗剂的子宫内膜异位症治疗剂 |
| CN109061139A (zh) * | 2018-06-19 | 2018-12-21 | 温州医科大学附属第医院 | 血清炎性生物标志物在防治急性缺血性脑梗死中的应用 |
| TW202519263A (zh) * | 2019-03-21 | 2025-05-16 | 美商再生元醫藥公司 | 含有抗il-33抗體之穩定調配物 |
| EP4114414A4 (en) * | 2020-03-06 | 2024-03-27 | The Regents of The University of Michigan | Serine protease inhibitors for suppressing or preventing anaphylactic reaction |
| KR20220152262A (ko) | 2020-03-13 | 2022-11-15 | 제넨테크, 인크. | 항-인터루킨-33 항체 및 이의 용도 |
| JP7578943B2 (ja) * | 2020-07-13 | 2024-11-07 | 学校法人自治医科大学 | 褥瘡治療剤 |
| CN114814242B (zh) * | 2022-06-10 | 2025-04-01 | 中日友好医院(中日友好临床医学研究所) | 一种诊断慢性阻塞性肺疾病患者肌肉减少症的血液学标志物 |
| EP4658247A1 (en) * | 2023-01-31 | 2025-12-10 | Vivacelle Bio, Inc. | Compositions and methods for treating hyperprocalcitonemia |
| KR102834740B1 (ko) * | 2023-04-10 | 2025-07-17 | 아주대학교산학협력단 | Hsp10 또는 이의 항체를 유효성분으로 포함하는 만성 자발적 두드러기의 진단을 위한 바이오마커 조성물 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4227454C1 (de) * | 1992-08-19 | 1994-02-03 | Henning Berlin Gmbh | Verfahren zur Früherkennung, zur Erkennung des Schweregrads sowie zur therapiebegleitenden Verlaufsbeurteilung einer Sepsis sowie Mittel zur Durchführung des Verfahrens |
| NZ549040A (en) * | 2004-02-17 | 2009-07-31 | Schering Corp | Use for interleukin-33 (IL33) and the IL-33 receptor complex |
| WO2010025393A2 (en) * | 2008-08-28 | 2010-03-04 | The Regents Of The University Of California | Protein biomarkers and methods for diagnosing kawasaki disease |
| JO3532B1 (ar) * | 2013-03-13 | 2020-07-05 | Regeneron Pharma | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها |
| KR20150127591A (ko) * | 2013-03-15 | 2015-11-17 | 리제너론 파아마슈티컬스, 인크. | Il-33 길항제 및 이의 용도 |
| BR112016008694A2 (pt) * | 2013-10-23 | 2017-10-03 | Genentech Inc | Métodos de previsão da reação de pacientes com asma, de previsão da capacidade de reação de pacientes com asma, de identificação de pacientes com asma, de tratamento de pacientes portadores de asma e de tratamento de asma, uso de um kit e kit |
| KR102687412B1 (ko) | 2015-10-06 | 2024-07-24 | 리제너론 파아마슈티컬스, 인크. | 인터루킨-33(il-33)-매개된 질환과 관련된 바이오마커 및 이의 용도 |
-
2016
- 2016-10-05 KR KR1020187009724A patent/KR102687412B1/ko active Active
- 2016-10-05 WO PCT/US2016/055502 patent/WO2017062456A2/en not_active Ceased
- 2016-10-05 HK HK19101754.3A patent/HK1259386A1/zh unknown
- 2016-10-05 EP EP16790463.0A patent/EP3359567A2/en active Pending
- 2016-10-05 AU AU2016333903A patent/AU2016333903B2/en active Active
- 2016-10-05 HK HK18115046.2A patent/HK1255972A1/zh unknown
- 2016-10-05 EA EA201890891A patent/EA201890891A1/ru unknown
- 2016-10-05 US US15/285,772 patent/US10005834B2/en active Active
- 2016-10-05 CA CA3000725A patent/CA3000725A1/en active Pending
- 2016-10-05 JP JP2018517626A patent/JP6858182B2/ja active Active
- 2016-10-05 MX MX2018004170A patent/MX2018004170A/es unknown
- 2016-10-05 MA MA050638A patent/MA50638A/fr unknown
- 2016-10-05 CN CN201680058610.4A patent/CN108137682A/zh active Pending
-
2018
- 2018-05-21 US US15/985,660 patent/US10851158B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017062456A3 (en) | 2017-05-18 |
| EA201890891A1 (ru) | 2018-09-28 |
| EP3359567A2 (en) | 2018-08-15 |
| KR20180053682A (ko) | 2018-05-23 |
| US10005834B2 (en) | 2018-06-26 |
| US20170096483A1 (en) | 2017-04-06 |
| AU2016333903A1 (en) | 2018-04-26 |
| CA3000725A1 (en) | 2017-04-13 |
| WO2017062456A2 (en) | 2017-04-13 |
| US10851158B2 (en) | 2020-12-01 |
| JP2018533557A (ja) | 2018-11-15 |
| MA50638A (fr) | 2020-08-05 |
| JP6858182B2 (ja) | 2021-04-14 |
| KR102687412B1 (ko) | 2024-07-24 |
| AU2016333903B2 (en) | 2021-07-08 |
| MX2018004170A (es) | 2018-06-06 |
| CN108137682A (zh) | 2018-06-08 |
| US20180258164A1 (en) | 2018-09-13 |
| HK1255972A1 (zh) | 2019-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1259386A1 (zh) | 与白介素-33 (il-33)介导的疾病有关的生物标志物及其用途 | |
| PH12019501120A1 (en) | Methods of treating inflammatory conditions | |
| EA201792642A1 (ru) | Способы диагностики для т-клеточной терапии | |
| BR112015009948A8 (pt) | Antagonistas de ativina-actrii, usos dos mesmos para tratamento de doenças ósseas e outros distúrbios e método para monitorar a eficácia do tratamento ou prevenção de uma doença óssea e outros distúrbios | |
| WO2016077366A8 (en) | Therapeutic and diagnostic methods for il-33-mediated disorders | |
| MY199027A (en) | Method for treating or preventing ophthalmological conditions | |
| WO2011141823A3 (en) | Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists | |
| EA201590655A8 (ru) | Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений | |
| EA201590654A1 (ru) | Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона | |
| EP4406536A3 (en) | Cystathionine beta-synthase enzyme for treatment of homocystinuria | |
| BR112017002637A2 (pt) | métodos para tratar ou prevenir condições oftalmológicas | |
| MX392677B (es) | Composiciones para usarse en el tratamiento de trastornos neurodegenerativos en una población particular de pacientes. | |
| WO2014197816A8 (en) | Stimulus responsive nanocomplexes and methods of use thereof | |
| EP4279127A3 (en) | Growth differentiation factor 15 as biomarker for metformin | |
| EA201790563A8 (ru) | Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой | |
| EA201691567A1 (ru) | Способы лечения легких травм головного мозга | |
| WO2017025928A3 (en) | Methods of treating ophthalmic disorders | |
| MX387839B (es) | Laminina para usarse en el tratamiento de una enfermedad, un trastorno o una afección de un endotelio de córnea. | |
| PH12015502687A1 (en) | Marker for acid sphingomyelinase disorders and uses thereof | |
| BR112019002355A2 (pt) | composições e métodos para prevenção de acidente vascular cerebral em pacientes pediátricos com anemia falciforme | |
| WO2013106766A3 (en) | THERAPEUTIC INDICATIONS OF miR-1291 | |
| MX2020006388A (es) | Biomarcadores para el diagnostico y pronostico de trastornos ectaticos de la cornea. | |
| WO2017059276A8 (en) | Therapeutic and diagnostic methods for autoimmune diseases and/or inflammation | |
| WO2017095918A3 (en) | Methods for treating cancer using rspo3 antagonists | |
| WO2019053116A8 (en) | Method for guidance of fluid therapy based on proadrenomedullin |